We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

135 hedge funds and large institutions have $934M invested in Vanda Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

26% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 43

15% more capital invested

Capital invested by funds: $812M → $934M (+$122M)

3% more funds holding

Funds holding: 131 → 135 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.55% less ownership

Funds ownership: 94.63% → 94.08% (-0.55%)

5% less call options, than puts

Call options by funds: $683K | Put options by funds: $722K

Holders
135
Holders Change
+4
Holders Change %
+3.05%
% of All Funds
3.09%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
54
Reduced
43
Closed
12
Calls
$683K
Puts
$722K
Net Calls
-$39K
Net Calls Change
+$1.13M

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$25.7M
2
First Manhattan
First Manhattan
New York
+$16M
3
BlackRock
BlackRock
New York
+$11.6M
4
State Street
State Street
Massachusetts
+$4.83M
5
Macquarie Group
Macquarie Group
Australia
+$4.62M

Top Sellers

Rank Fund Capital Flow
1
RCAMU
Rothschild & Co Asset Management US
Connecticut
-$15.1M
2
Millennium Management
Millennium Management
New York
-$10.1M
3
SCM
Stonepine Capital Management
Oregon
-$6.43M
4
AC
Armistice Capital
New York
-$6.29M
5
GPP
Great Point Partners
Connecticut
-$5.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$94.5M +$11.6M +693,922 +16%
CCM
2
Consonance Capital Management
New York
$87.8M +$25.7M +1,536,768 +50%
PAI
3
Palo Alto Investors
California
$79.2M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$63.6M +$3.38M +202,308 +6%
ACA
5
Avoro Capital Advisors
New York
$53.3M +$418K +25,000 +0.9%
Macquarie Group
6
Macquarie Group
Australia
$48.7M +$4.62M +276,057 +12%
AC
7
Armistice Capital
New York
$42.4M -$6.29M -376,000 -14%
State Street
8
State Street
Massachusetts
$41.4M +$4.83M +288,921 +15%
Renaissance Technologies
9
Renaissance Technologies
New York
$32M +$689K +41,200 +3%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$26.7M – – –
Fidelity Investments
11
Fidelity Investments
Massachusetts
$25M – – –
Invesco
12
Invesco
Georgia
$23.3M -$1.16M -69,487 -5%
Morgan Stanley
13
Morgan Stanley
New York
$21.9M -$1.4M -83,546 -7%
CAM
14
Cormorant Asset Management
Massachusetts
$18.2M – – –
First Manhattan
15
First Manhattan
New York
$18.2M +$16M +956,666 +478,333%
Prudential Financial
16
Prudential Financial
New Jersey
$15.8M -$293K -17,540 -2%
TA
17
Teachers Advisors
New York
$13.7M +$153K +9,173 +1%
TCIM
18
TIAA CREF Investment Management
New York
$13.1M +$2.83M +169,254 +33%
Northern Trust
19
Northern Trust
Illinois
$12.9M +$1.53M +91,539 +16%
SCM
20
Stonepine Capital Management
Oregon
$11.4M -$6.43M -384,584 -39%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$10.8M +$1.07M +63,774 +13%
RCAMU
22
Rothschild & Co Asset Management US
Connecticut
$8.57M -$15.1M -902,555 -67%
Charles Schwab
23
Charles Schwab
California
$7.47M +$164K +9,802 +3%
Millennium Management
24
Millennium Management
New York
$7.44M -$10.1M -605,873 -61%
Two Sigma Investments
25
Two Sigma Investments
New York
$6.76M +$3.02M +180,314 +103%
1
2 3 4 5

VNDA Hedge Fund Activity: Q2 2018 in Review

135 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2018, worth a combined $934M — up 15% from $812M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VNDA positions and 12 closed out — a net gain of 4 holders — while 54 added to existing stakes and 43 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $25.7M. The largest seller was Rothschild & Co Asset Management US, cutting an estimated $15.1M.

  • 135 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2018, up from 131 in Q1 2018.
  • Funds reported $934M of Vanda Pharmaceuticals stock for Q2 2018, up 15% quarter-over-quarter.
  • 16 funds opened new Vanda Pharmaceuticals positions in Q2 2018 and 12 closed out, a net change of +4 holders.
  • The largest Vanda Pharmaceuticals buyer in Q2 2018 was Consonance Capital Management, an estimated $25.7M added.
  • The largest Vanda Pharmaceuticals seller in Q2 2018 was Rothschild & Co Asset Management US, an estimated $15.1M sold.

Based on aggregated 13F filings for Q2 2018.